These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28522427)

  • 1. Association of chitosan and aluminium as a new adjuvant strategy for improved vaccination.
    Lebre F; Bento D; Ribeiro J; Colaço M; Borchard G; de Lima MCP; Borges O
    Int J Pharm; 2017 Jul; 527(1-2):103-114. PubMed ID: 28522427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust Immune Responses Elicited by a Hybrid Adjuvant Based on β-Glucan Particles from Yeast for the Hepatitis B Vaccine.
    Liu H; Meng Z; Wang H; Zhang S; Huang Z; Geng X; Guo R; Wu Z; Hong Z
    ACS Appl Bio Mater; 2021 Apr; 4(4):3614-3622. PubMed ID: 35014447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles.
    Lebre F; Pedroso de Lima MC; Lavelle EC; Borges O
    Int J Pharm; 2018 Dec; 552(1-2):7-15. PubMed ID: 30244149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
    Pawar D; Mangal S; Goswami R; Jaganathan KS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen.
    Jesus S; Soares E; Borchard G; Borges O
    Nanomedicine (Lond); 2017 Oct; 12(19):2335-2348. PubMed ID: 28868964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response.
    Pawar D; Jaganathan KS
    Drug Deliv; 2016; 23(1):185-94. PubMed ID: 24825494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity.
    Lugade AA; Bharali DJ; Pradhan V; Elkin G; Mousa SA; Thanavala Y
    Nanomedicine; 2013 Oct; 9(7):923-34. PubMed ID: 23542018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Conjugated Chitosan-Based Nanoparticles to Proteic Antigens Elicit Similar Humoral Immune Responses to Those Obtained with Alum.
    Izaguirre-Hernández IY; Mellado-Sánchez G; Mondragón-Vásquez K; Thomas-Dupont P; Sánchez-Vargas LA; Hernández-Flores KG; Mendoza-Barrera C; Altuzar V; Cedillo-Barrón L; Hernández-Flores KG; Mendoza-Barrera C; Altuzar V; Cedillo-Barrón L; Vivanco-Cid H
    J Nanosci Nanotechnol; 2017 Jan; 17(1):846-52. PubMed ID: 29634187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
    Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
    Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chitosan:β-glucan particles as a new adjuvant for the hepatitis B antigen.
    Soares E; Jesus S; Borges O
    Eur J Pharm Biopharm; 2018 Oct; 131():33-43. PubMed ID: 30048745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
    Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
    Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics.
    Tafaghodi M; Saluja V; Kersten GF; Kraan H; Slütter B; Amorij JP; Jiskoot W
    Vaccine; 2012 Aug; 30(36):5341-8. PubMed ID: 22749834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
    Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
    Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA.
    Shen E; Li L; Li L; Feng L; Lu L; Yao Z; Lin H; Wu C
    Cell Mol Immunol; 2007 Apr; 4(2):113-20. PubMed ID: 17484805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single dose HBsAg CS-γ-PGA nanogels induce potent protective immune responses against HBV infection.
    Wang H; Han Q; Zhao H; Xu D; Zhang J
    Eur J Pharm Biopharm; 2018 Mar; 124():82-88. PubMed ID: 29247691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles.
    Jesus S; Soares E; Costa J; Borchard G; Borges O
    Int J Pharm; 2016 May; 504(1-2):59-69. PubMed ID: 26976502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
    Prego C; Paolicelli P; Díaz B; Vicente S; Sánchez A; González-Fernández A; Alonso MJ
    Vaccine; 2010 Mar; 28(14):2607-14. PubMed ID: 20096389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen.
    Xie Y; Sun HX; Li D
    Vaccine; 2009 Jan; 27(5):757-64. PubMed ID: 19041358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
    Song ES; Park SA; Kim SH; Cho YJ; Ahn BY; Ahn BC; Lee NG
    FEMS Immunol Med Microbiol; 2007 Dec; 51(3):496-504. PubMed ID: 17877731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.